Back to Clinical Trials Overview

Your search for "Liver Disorders" returned 25 results:


Natural History Study of Acute Hepatic Porphyria (AHP) with Recurrent Attacks
Principal Investigator(s): Manisha Balwani

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis
Principal Investigator(s): Meena Bansal

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects with Chronic Hepatitis B who are Virologically Suppressed
Principal Investigator(s): Ritu Agarwal

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled,Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis
Principal Investigator(s): Meena Bansal

A Phase IIb, double blind randomized, controlled clinical trial, to evaluate the efficacy and safety of two Aramchol doses versus placebo in patients with Non-Alcoholic Steatohepatitis (NASH)
Principal Investigator(s): Charissa Chang

A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Joseph Odin

A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects with Primary Sclerosing Cholangitis (PSC)
Principal Investigator(s): Jawad Ahmad

A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis Patients Who Are Refractory or Intolerant to Current Therapies
Principal Investigator(s): Joseph Odin

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis
Principal Investigator(s): Charissa Chang

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
Principal Investigator(s): Charissa Chang

Characterization of Acute HCV Infection
Principal Investigator(s): Fierer, Daniel S

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Donald Kotler

Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV
Principal Investigator(s): David Ferris

A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis (CENTAUR)
Principal Investigator(s): Meena Bansal

HCC BRIDGE study: Bridge to better outcomes in HCC
Principal Investigator(s): Schwartz, Myron MD

An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
Principal Investigator(s): Joseph Odin

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by Electroporation in Select Nucleos(t)ide Analogue-treated, Chronic Hepatitis B Patients
Principal Investigator(s): Douglas Dieterich

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis
Principal Investigator(s): Charissa Chang

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
Principal Investigator(s): Peter Gorevic

A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects with Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
Principal Investigator(s): Ponni Perumalswami

A Long Term Follow-up Registry Study for Subjects Who Achieve A Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Ponni Perumalswami

A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
Principal Investigator(s): Donald Kotler

An Open-Label Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
Principal Investigator(s): Douglas Dieterich

A Phase 2 Randomized Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the treatment of subjects with chronic hepatitis B and who are currently not on treatment
Principal Investigator(s): Jennifer Leong